je.st
news
Tag: vaccines
Survey: 74% might pull kids from day care over vaccines
2014-11-18 16:26:00| Biotech - Topix.net
Nationally, more than 30% of 2-year-olds are not up-to-date on vaccines, according to the Centers for Disease Control and Prevention. Survey: 74% might pull kids from day care over vaccines Nationally, more than 30% of 2-year-olds are not up-to-date on vaccines, according to the Centers for Disease Control and Prevention.
Scientists grapple with ethics in rush to release Ebola vaccines
2014-09-28 22:07:03| Biotech - Topix.net
Normally it takes years to prove a new vaccine is both safe and effective before it can be used in the field. But with hundreds of people dying a day in the worst ever outbreak of Ebola, there is no time to wait.
Tags: release
ethics
rush
scientists
WHO sees smallscale use of experimental Ebola vaccines in January
2014-09-27 11:43:13| Biotech - Topix.net
The World Health Organisation said on Friday it expected to begin small-scale use of two experimental Ebola vaccines in West Africa early next year and in the meantime transfusions of survivors' blood may offer the best hope of treatment. WHO is working with pharmaceutical companies and regulators to accelerate the use of a range of potential treatments to fight the disease, a senior WHO official said.
Tags: january
experimental
sees
vaccines
Tools for the Design of Vaccines to Help Reduce Clinical Failure
2014-09-11 16:23:44| drugdiscoveryonline Home Page
If you are involved in the pharma industry, then you are interested in saving lives. In the area of preventative medicine, therapeutic vaccines have proven to have a tremendous impact on the ability to save millions of lives. Similar to pharmaceuticals, vaccine development can take over 10 years and less than 10 percent of candidates reach commercialization. Reducing the cost of failure and increasing the chances of clinical success for vaccines is beneficial to both the pharma industry and those being treated for or protected from disease. Dr. Noel Smith, Senior Group Leader, Lonza Biologics Lonza understands this need and how ensuring the design and development of efficacious vaccines is critical for worldwide health. To address this, Dr. Noel Smith, Senior Group Leader, and the Applied Protein Services team at Lonza launched the Epibase™ Platform of in silico and in vitro immunogenicity screening services to help increase the chances of success for anyone aiming to develop safe and potent vaccines. “Our tools help researchers in the discovery stage of vaccine design and development to optimize their molecules before they progress into manufacturing for clinical trials,” says Dr. Smith. “Early assessment and optimization of immune responses allows you to focus your R&D resources on a smaller number of vaccine candidates with the greatest chance of success.”
Tags: design
tools
reduce
failure
Survey Shows IBR, BVD Vaccines Most Important
2014-09-10 15:52:49| Beef
A survey of veterinarians and beef producers, sponsored by Zoetis, shows that protection against abortions caused by infectious bovine rhinotracheitis (IBR) in cows and fetal protection against bovine viral diarrhea persistent infection (BVD-PI) in calves is the most important vaccine consideration.1 Beyond that, respondents say that just sticking a needle in the cow isn’t enough—the vaccine has to demonstrate duration of immunity and safety. read more
Tags: important
shows
survey
vaccines
Sites : [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »